Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)
Featured Articles
(Agios) Feb 15, 2018 - Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for ivosidenib (AG-120) for the treatment of patients with relapsed or...
Read Article
(MarketWatch) Feb 14, 2018 - The sBLA for BLINCYTO was accepted by the FDA for priority review, and a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2018 has been set.
Read Article
Latest Articles
February 20, 2018
February 16, 2018
February 14, 2018
February 13, 2018
February 09, 2018
February 09, 2018
February 09, 2018
February 07, 2018
View More
News Commentary
Editor Image
21 Apr, 2017 | by Dean Gesme, MD
This will only determine how much delay is allowed by the courts and how...
View Comment
Editor Image
26 Apr, 2017 | by Howard S. Hochster, MD
Fascinating legal wrangling as the Supremes parse the wording of the BPCIA...
View Comment
View More
OBR Green
There are no Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis) OBR Green articles.
OBR Blog
There are no Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis) blog entries.